Research LettersEffect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease
References (5)
- et al.
Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele
Neurosci Lett
(1997) - et al.
Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model
Ann Neurol
(2000)
Cited by (39)
Apolipoprotein E DNA methylation and posttraumatic stress disorder are associated with plasma ApoE level: A preliminary study
2019, Behavioural Brain ResearchCitation Excerpt :The APOE-ε4 allele has been associated with the development of late-onset Alzheimer's disease (AD) [3]. However, amyloid beta (Aβ) peptide accumulation in the brains of AD patients has been shown to be independent of APOE genotype [4]. Additionally, the APOE-ε4 allele has been associated with poor outcome following stroke or brain injury [5], perhaps through an increased affinity for Aβ protein aggregation [6], or a decreased efficacy in promoting neuronal growth and branching [7].
Genetics of Alzheimer's disease: New evidences for an old hypothesis?
2011, Current Opinion in Genetics and DevelopmentCitation Excerpt :In brain tissue from AD patients, the quantity of APOE mRNA is inversely correlated with the quantity of amyloid deposits [33]. Moreover, polymorphisms within the APOE promoter, associated with decreases in the in vitro and in vivo expression of this gene [33–35], are also associated with (i) an increase in the quantity of amyloid deposits [33,36] and (ii) a greater risk of developing AD [37]. If we then consider genes characterized by GWAS, CLU is one the most abundantly expressed apolipoproteins in the central nervous system [38,39].
Chapter 4 Alzheimer's Disease in Adults with Down Syndrome
2008, International Review of Research in Mental RetardationCitation Excerpt :The Apolipoprotein E (APOE) gene, located on chromosome 19, is the most important genetic risk factor found thus far for late onset Alzheimer's disease in the typically developing population (Corder et al., 1993; Saunders et al., 1993). The APOE gene, which occurs predominately in three variants or alleles (i.e., ε2, ε3, or ε4), is involved in cholesterol transport and lipid metabolism in plasma (Dupuy et al., 2001) as well as accumulation of β‐amyloid protein in the brains of typically developing elderly people, both with and without Alzheimer's disease (Lambert et al., 2001; Polvikowski et al., 1995]. In numerous studies, participants with Alzheimer's disease have been found to have higher frequencies of the APOE ε4 allele compared with those with other APOE genotypes, and those with the ε4 allele have an earlier age of onset of Alzheimer's disease (Corder et al., 1993; de‐Andrade, Larrandaburu, Callegari‐Jacques, Gastaldo, & Hutz, 2000; Isbir et al., 2001; Mayeux et al., 1993).
APOE promoter polymorphisms and dementia in the elderly
2004, Neuroscience LettersGenetic complexity of Alzheimer's disease
2004, Revue NeurologiqueAmyloid precursor protein (APP) and the biology of proteolytic processing: Relevance to Alzheimer's disease
2003, International Journal of Biochemistry and Cell Biology